A PYMNTS Company

Johnson & Johnson to Acquire Intra-Cellular Therapies in $14.6 Billion Deal

By  |  January 14, 2025

Johnson & Johnson (J&J) announced on Monday its plan to acquire neurological drug maker Intra-Cellular Therapies in a $14.6 billion deal, marking its largest acquisition in over two years. The move is aimed at bolstering J&J’s presence in the lucrative brain disease treatment market, according to Reuters.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The acquisition comes as J&J continues to reshape its business following the spin-off of its consumer health unit in 2023. Over the past few years, the company has made strategic investments to strengthen its pharmaceutical and medical device divisions. Notably, J&J struck a $13.1 billion deal to purchase Shockwave Medical in 2024, demonstrating its commitment to expanding its healthcare portfolio.

    Speaking at a prominent industry conference in San Francisco, J&J CEO Joaquin Duato highlighted the significance of this latest move. “These deals do not happen every day, and as a matter of fact, for us, larger deals are more outliers,” he said, per Reuters.

    Intra-Cellular Therapies is best known for its oral drug Caplyta, which is approved in the U.S. to treat schizophrenia and bipolar depression. The acquisition will provide J&J with immediate access to the drug, as well as several experimental treatments currently in development. Caplyta generated $481.3 million in sales in the first nine months of 2024, with analysts predicting that annual sales could surpass $1 billion next year. Furthermore, the drug is not expected to face generic competition until 2040, according to data compiled by LSEG.

    J&J’s offer to buy Intra-Cellular Therapies includes a payment of $132 per share, representing a 39% premium over the stock’s closing price on Friday. Following the announcement, Intra-Cellular shares jumped 34% to $128 in afternoon trading, while J&J’s stock rose by 1.5%.

    The acquisition is part of a broader trend in the pharmaceutical sector, with experts predicting increased dealmaking in 2025. Bankers attending the San Francisco conference believe the industry could see more than $10 billion in transactions this year, driven by expectations of reduced antitrust scrutiny after President-elect Donald Trump assumes office on January 20, according to Reuters.

    Source: Reuters